| Nov 8 |
Vor Biopharma GAAP EPS of -$0.40
|
| Nov 7 |
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
|
| Sep 30 |
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
|
| Sep 5 |
Vor Bio stock rallies post-market on trem-cel study data
|
| Sep 5 |
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
|
| Sep 5 |
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely
|
| Aug 9 |
Vor Biopharma GAAP EPS of -$0.41
|
| Aug 8 |
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
|
